Heparanase Regulation of Cancer, Autophagy and Inflammation: New Mechanisms and Targets for Therapy

Overview

Journal FEBS J

Specialty Biochemistry

Date 2016 Oct 21

PMID 27758044

Citations 104

Authors

Ralph D Sanderson

Michael Elkin

Alan C Rapraeger

Neta Ilan

Israel Vlodavsky

Affiliations

Soon will be listed here.

Abstract

Because of its impact on multiple biological pathways, heparanase has emerged as a major regulator of cancer, inflammation and other disease processes. Heparanase accomplishes this by degrading heparan sulfate which regulates the abundance and location of heparin-binding growth factors thereby influencing multiple signaling pathways that control gene expression, syndecan shedding and cell behavior. In addition, heparanase can act via nonenzymatic mechanisms that directly activate signaling at the cell surface. Clinical trials testing heparanase inhibitors as anticancer therapeutics are showing early signs of efficacy in patients further emphasizing the biological importance of this enzyme. This review focuses on recent developments in the field of heparanase regulation of cancer and inflammation, including the impact of heparanase on exosomes and autophagy, and novel mechanisms whereby heparanase regulates tumor metastasis, angiogenesis and chemoresistance. In addition, the ongoing development of heparanase inhibitors and their potential for treating cancer and inflammation are discussed.

Citing Articles

Autophagy in brain tumors: molecular mechanisms, challenges, and therapeutic opportunities.

Zhang J, Zhang J, Yang C J Transl Med. 2025; 23(1):52.

PMID: 39806481 PMC: 11727735. DOI: 10.1186/s12967-024-06063-0.

Quantitative proteomics and multi-omics analysis identifies potential biomarkers and the underlying pathological molecular networks in Chinese patients with multiple sclerosis.

Yang F, Zhao L, Yang W, Chao S, Ling Z, Sun B BMC Neurol. 2024; 24(1):423.

PMID: 39478468 PMC: 11526627. DOI: 10.1186/s12883-024-03926-3.

Heparanase-induced endothelial glycocalyx degradation exacerbates lung ischemia/reperfusion injury in male mice.

Noda K, Atale N, Al-Zahrani A, Furukawa M, Snyder M, Ren X Physiol Rep. 2024; 12(20):e70113.

PMID: 39448392 PMC: 11502304. DOI: 10.14814/phy2.70113.

Proteomic analysis reveals key differences in pro-stromal corneal tissue between highly myopic males and females.

Cui G, Di Y, Yang S, Chen Y, Li Y, Chen D Front Med (Lausanne). 2024; 11:1406748.

PMID: 39219796 PMC: 11361967. DOI: 10.3389/fmed.2024.1406748.

Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function.

Padin J, Perez-Ortiz J, Redondo-Calvo F Int J Mol Sci. 2024; 25(14).

PMID: 39062796 PMC: 11277036. DOI: 10.3390/ijms25147553.

References

Floer M, Gotte M, Wild M, Heidemann J, Salem Gassar E, Domschke W . Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol. 2009; 176(1):146-57. PMC: 2797877. DOI: 10.2353/ajpath.2010.080639. View

Ramani V, Pruett P, Thompson C, DeLucas L, Sanderson R . Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem. 2012; 287(13):9952-9961. PMC: 3322978. DOI: 10.1074/jbc.M111.330803. View

Rivara S, Milazzo F, Giannini G . Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem. 2016; 8(6):647-80. DOI: 10.4155/fmc-2016-0012. View

Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M . Role of endothelial heparanase in delayed-type hypersensitivity. Blood. 2005; 107(9):3609-16. PMC: 1444937. DOI: 10.1182/blood-2005-08-3301. View

Escobar Galvis M, Jia J, Zhang X, Jastrebova N, Spillmann D, Gottfridsson E . Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol. 2007; 3(12):773-8. DOI: 10.1038/nchembio.2007.41. View

You H, Gao T, Cooper T, Reeves W, Awad A . Macrophages directly mediate diabetic renal injury. Am J Physiol Renal Physiol. 2013; 305(12):F1719-27. PMC: 3882451. DOI: 10.1152/ajprenal.00141.2013. View

Goldshmidt O, Nadav L, Aingorn H, Irit C, Feinstein N, Ilan N . Human heparanase is localized within lysosomes in a stable form. Exp Cell Res. 2002; 281(1):50-62. DOI: 10.1006/excr.2002.5651. View

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

Naparstek Y, Cohen I, Fuks Z, Vlodavsky I . Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature. 1984; 310(5974):241-4. DOI: 10.1038/310241a0. View

10.

Johnson G, Brunn G, Kodaira Y, Platt J . Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol. 2002; 168(10):5233-9. DOI: 10.4049/jimmunol.168.10.5233. View

11.

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

12.

Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R . Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer. 2005; 118(7):1609-17. DOI: 10.1002/ijc.21552. View

13.

Cha J, Hyun Y, Lee M, Kim J, Nam D, Song H . Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology. 2013; 154(6):2144-55. DOI: 10.1210/en.2012-2080. View

14.

Purushothaman A, Chen L, Yang Y, Sanderson R . Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem. 2008; 283(47):32628-36. PMC: 2583309. DOI: 10.1074/jbc.M806266200. View

15.

Shteingauz A, Boyango I, Naroditsky I, Hammond E, Gruber M, Doweck I . Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy. Cancer Res. 2015; 75(18):3946-57. PMC: 4573896. DOI: 10.1158/0008-5472.CAN-15-0037. View

16.

Dredge K, Hammond E, Handley P, Gonda T, Smith M, Vincent C . PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011; 104(4):635-42. PMC: 3049593. DOI: 10.1038/bjc.2011.11. View

17.

Friand V, David G, Zimmermann P . Syntenin and syndecan in the biogenesis of exosomes. Biol Cell. 2015; 107(10):331-41. DOI: 10.1111/boc.201500010. View

18.

Casu B, Vlodavsky I, Sanderson R . Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb. 2009; 36(3-4):195-203. PMC: 2768601. DOI: 10.1159/000175157. View

19.

Baietti M, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A . Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012; 14(7):677-85. DOI: 10.1038/ncb2502. View

20.

Lapidot M, Barash U, Zohar Y, Geffen Y, Naroditsky I, Ilan N . Involvement of Heparanase in Empyema: Implication for Novel Therapeutic Approaches. J Clin Cell Immunol. 2015; 6(1). PMC: 4441338. DOI: 10.4172/2155-9899.1000290. View